공고 • Jul 20
Astonea Labs Limited to Report Fiscal Year 2026 Final Results on Jul 24, 2026 Astonea Labs Limited announced that they will report fiscal year 2026 final results at 12:15 PM, Indian Standard Time on Jul 24, 2026 New Risk • Jun 26
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin). Market cap is less than US$100m (₹2.76b market cap, or US$29.2m). Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹268, the stock trades at a trailing P/E ratio of 60.8x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 98% over the past year. New Risk • Jun 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (72% net debt to equity). Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₹3.16b market cap, or US$33.0m). New Risk • May 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (72% net debt to equity). Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹2.42b market cap, or US$25.3m). 공고 • May 25
Astonea Labs Limited to Report Second Half, 2026 Results on May 30, 2026 Astonea Labs Limited announced that they will report second half, 2026 results on May 30, 2026 Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹227, the stock trades at a trailing P/E ratio of 51.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. 공고 • Dec 04
Astonea Labs Limited, Annual General Meeting, Dec 27, 2025 Astonea Labs Limited, Annual General Meeting, Dec 27, 2025, at 11:00 Indian Standard Time. Location: mercure hotel, plot no 51, tribune chowk, industrial area, phase ii - 160002, chandigarh, India 공고 • Dec 03
Astonea Labs Limited Announces Executive Changes Astonea Labs Limited in its board of directors meeting held on 3 December, 2025 approved the appointment of Mr. Ankit Kapoor as the Company Secretary and Compliance Officer of the Company with effect from 3 December, 2025, in accordance with the provisions of Section 203 of the Companies Act, 2013. The Board also acknowledged and accepted the retirement of Mr. Pardeep Singh (DIN: 10345015) from the position of Director of the Company, as he is liable to retire by rotation at the ensuing Annual General Meeting and has not offered himself for re-appointment. The Board placed on record its appreciation for his valuable contributions during his tenure. 공고 • Nov 30
Astonea Labs Limited (BSE:544409) agreed to acquire an unknown minority stake in Damaira Pharmaceuticals Private Limited. Astonea Labs Limited (BSE:544409) agreed to acquire an unknown minority stake in Damaira Pharmaceuticals Private Limited on November 28, 2025.
The transaction is subject to approval of offer by acquirer board. Reported Earnings • Nov 11
First half 2026 earnings released: EPS: ₹1.48 (vs ₹3.00 in 1H 2025) First half 2026 results: EPS: ₹1.48 (down from ₹3.00 in 1H 2025). Revenue: ₹663.9m (up 29% from 1H 2025). Net income: ₹14.2m (down 39% from 1H 2025). Profit margin: 2.1% (down from 4.5% in 1H 2025). The decrease in margin was driven by higher expenses. 공고 • Nov 07
Astonea Labs Limited to Report Q2, 2026 Results on Nov 10, 2025 Astonea Labs Limited announced that they will report Q2, 2026 results on Nov 10, 2025 Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹169, the stock trades at a trailing P/E ratio of 46.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Board Change • Jun 03
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. MD & Director Ashish Gulati is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
